Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507852 · ClinicalTrials.gov registry record
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
A clinical trial of Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, sponsored by Novartis.
- Completed
- Registry status
- 95
- Enrollment target
- 1
- Study location
NCT06507852 is a study of Hypercholesterolemia and Atherosclerotic Cardiovascular Disease that has completed, run by Novartis. The registered enrollment target is 95 participants, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06507852, a study of Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia (FH) administered inclisiran in a real-world setting in Austria.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-07-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06507852
The ClinicalTrials.gov registry entry for NCT06507852 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypercholesterolemia appearing as the primary indexed condition, and to 0 interventions.
NCT06507852 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06507852 about?
NCT06507852 is a clinical study titled "A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia". This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia (FH) administered inclisiran in a real-world setting in Austria.
What is the current status of trial NCT06507852?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2022-10-03. Estimated completion is 2023-07-06.
What conditions does trial NCT06507852 study?
This clinical trial studies the following conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Who is sponsoring clinical trial NCT06507852?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507852 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics of Butyrate Tablet BKR-017
RECRUITING
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
RECRUITING · NA
-
Pharmacogenomic Informed Statin Prescribing
RECRUITING · NA
-
Causes and Natural History of Dyslipidemias
RECRUITING
-
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Hypercholesterolemia
All registered trials for this condition
Atherosclerotic Cardiovascular Disease
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.